

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
---	--

Dear Sir/ Madam,

Sub: Update on intimation on acquisition of remaining stake in Wockhardt Biologics Limited [CIN: U24299MH2021PLC363201] making it a wholly owned subsidiary

In continuation to our communication relating to Outcome of the Board Meeting dated 8th November, 2021; and pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Schedule III of Listing Regulations, we wish to inform to the Exchanges that the Board of Directors of the Company has approved the acquisition of remaining stake in Wockhardt Biologics Limited ("WBL") (CIN: U24299MH2021PLC363201) from the shareholders of WBL, making it a wholly owned subsidiary of the Company.

The information required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure A.

Kindly take the same on record please.

Thanking you,

For **Wockhardt Limited**



Debashis Dey
Company Secretary

Encl: As above



Sr. No.	Disclosure requirements	Disclosure by the Company
1	Name of the target entity, details in brief such as size, turnover etc.;	Name: Wockhardt Biologics Limited ('WBL') Authorised Subscribed & paid up Capital: 50,000 equity share of Rs. 10 /- each aggregating to Rs. 5,00,000/- Turnover: Yet to start the business operations
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	The remaining stake in WBL shall be acquired from the existing shareholders, who are also part of the Promoter /Group entities of the Company.
3	Industry to which the entity being acquired belongs;	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	WBL shall be engaged in pharmaceutical business, and the acquisition of its entire stake is likely result in operational efficiency & synergy.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
6	Indicative time period for completion of the acquisition;	The process for acquisition of remaining stake has been initiated and will be completed within a reasonable period.
7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash
8	Cost of acquisition or the price at which the shares are acquired	Rs. 1,75,100 (at face value)
9	Percentage of shareholding / control acquired and / or number of shares acquired	~35 percentage (17,510 equity shares of Rs. 10/- each (at face value) aggregating to Rs. 1,75,100)
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Date of Incorporation: 2 nd July, 2021 CIN: U24299MH2021PLC363201. WBL is yet to commence the business.

